Costs and benefits of rivastigmine treatment for Alzheimer's disease in the US

被引：0

作者：

Ofman, J

Hauber, B

Deal, L

Mauskopf, J

Snyder, E

机构：

[1] Zynx Hlth Incorp, Beverly Hills, CA USA

[2] Res Triangle Inst, Res Triangle Pk, NC 27709 USA

[3] Novartis Pharma AG, E Hanover, NJ USA

来源：

NEUROBIOLOGY OF AGING | 2002年 / 23卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

476

引用

页码：S126 / S126

页数：1

共 50 条

[21] Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand
Kulkantrakorn, Kongkiat
Tanyakitpisal, Panas
Towanabut, Somchai
Dejthevaporn, Charungthai
Rangseekajee, Poonsri
Pongpakdee, Sunsanee
Laptikultham, Somsak
Rodprasert, Kritsada
Setthawatcharawanich, Suwanna
Thinkhamrop, Bandit
PSYCHOGERIATRICS, 2013, 13 (01) : 1 - 8
[22] Potential savings in the cost of caring for Alzheimer's disease treatment with rivastigmine
Linkins, KW
Lloyd, LR
Hjelmstad, GO
Strausbaugh, HJ
PHARMACOECONOMICS, 2000, 18 (06) : 609 - 610
[23] Disease stage in Alzheimer disease and treatment effects of rivastigmine
Kurz, A
Farlow, M
Quarg, P
Spiegel, R
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2004, 18 (03): : 123 - 128
[24] Benefits of combination treatment in Alzheimer's disease
Gauthier, S.
EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 354 - 354
[25] Alzheimer's disease: the benefits of early treatment
Gauthier, SG
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 11 - 16
[26] Long-term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer's disease: Results following two years of treatment
Farlow, M
Messina, J
Anand, R
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (08) : S108 - S108
[27] Alzheimer's disease:: efficacy and tolerance of rivastigmine
Hébert, M
PRESSE MEDICALE, 1999, 28 (32): : 1757 - 1758
[28] Quetiapine and rivastigmine for agitation in Alzheimer’s disease
Raymond L. Ownby
Current Psychiatry Reports, 2006, 8 (1) : 10 - 10
[29] The response of patients with Alzheimer's disease to rivastigmine treatment is predicted by the rate of disease progression
Farlow, MR
Hake, AM
Messina, J
Veach, J
Anand, R
NEUROLOGY, 2000, 54 (07) : A469 - A470
[30] Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review
Kurz, A.
Farlow, M.
Lefevre, G.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (05) : 799 - 805

← 1 2 3 4 5 →